Wednesday, March 05, 2025 8:52:36 AM
A years woth of info here:
https://www.reddit.com/r/Livimmune/comments/1j3p4jf/cytodyn_science_news_since_early_2024_by_disease/
What a summary!!
Recent CYDY News
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/02/2025 10:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 01:40:20 PM
- CytoDyn Announces Resolution of Class Action Lawsuit • GlobeNewswire Inc. • 12/01/2025 01:30:00 PM
- CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 11/24/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2025 10:15:12 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/04/2025 10:15:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/03/2025 10:15:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2025 01:38:18 PM
- CytoDyn Secures $30 Million Commitment from Yorkville Advisors • GlobeNewswire Inc. • 11/03/2025 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/10/2025 12:30:21 PM
- CytoDyn to Present at the LD Micro Main Event XIX Investor Conference • GlobeNewswire Inc. • 10/09/2025 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/30/2025 09:15:05 PM
- September 2025 Letter to Shareholders • GlobeNewswire Inc. • 09/30/2025 12:30:55 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/29/2025 08:45:25 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/29/2025 08:30:48 PM
- CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity • GlobeNewswire Inc. • 09/25/2025 12:30:00 PM
Closing the Intent-to-Execution Gap May Define Next Wave of AI Investment • WLDS • Feb 17, 2026 9:00 AM
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A • ARWR • Feb 17, 2026 9:00 AM
UPDATE: Hydromer, Inc. Announces Expansion Into High-Speed Automated Coating and UV Cure Equipment Manufacturing • HYDI • Feb 10, 2026 10:58 AM
MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System • MWAI • Feb 10, 2026 8:45 AM
LaFleur Minerals Reports Assay Results Highlighting 2.05 g/t Au over 158.25 metres, Confirming Strong Gold Continuity at Swanson Gold Project • LFLRF • Feb 5, 2026 5:29 AM
DRCR Begins Rollout of New Business Model • DRCR • Feb 4, 2026 12:42 PM
